NDAORALTABLET
Approved
Apr 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TINDAL (acetophenazine maleate) is an oral antipsychotic tablet approved in 1961 by Merck & Co. as an NDA product. The drug treats psychiatric conditions through dopamine antagonism, though specific indications are not detailed in available data. It represents a legacy first-generation antipsychotic with a long clinical history.
LOE Approaching
With LOE approaching, the brand is in managed decline with minimal new hiring; legacy product teams focus on market optimization and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TINDAL offers minimal career growth opportunity due to its LOE approaching status and zero linked job openings. Roles are typically defensive, focused on maintaining existing contracts and managing generic supply rather than driving innovation or growth.
Generic Product ManagerMedical Science Liaison (Institutional Psychiatry)
Worked on TINDAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.